# Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain

> **NCT01864265** · PHASE3 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 156 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab Pegol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01864265
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2019-06-30
- **Final completion:** 2020-01-10
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01864265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01864265, "Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01864265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*